UA87843C2 - Применение пептидных соединений для лечения расстройств функционирования мотонейронов или/и периферических невропатий - Google Patents

Применение пептидных соединений для лечения расстройств функционирования мотонейронов или/и периферических невропатий

Info

Publication number
UA87843C2
UA87843C2 UAA200612858A UAA200612858A UA87843C2 UA 87843 C2 UA87843 C2 UA 87843C2 UA A200612858 A UAA200612858 A UA A200612858A UA A200612858 A UAA200612858 A UA A200612858A UA 87843 C2 UA87843 C2 UA 87843C2
Authority
UA
Ukraine
Prior art keywords
peptide compounds
peripheral neuropathies
motoneuron diseases
treating
treating motoneuron
Prior art date
Application number
UAA200612858A
Other languages
English (en)
Ukrainian (uk)
Inventor
Томас Штьор
Original Assignee
Шварц Фарма Аг
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Шварц Фарма Аг filed Critical Шварц Фарма Аг
Publication of UA87843C2 publication Critical patent/UA87843C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychology (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Это изобретение направлено на применение одного из классов пептидных соединений для лечения бокового амиотрофического склероза (ALS) и других форм заболеваний, которые имеют отношение к мотонейронам, и периферических невропатий.
UAA200612858A 2004-06-09 2005-06-08 Применение пептидных соединений для лечения расстройств функционирования мотонейронов или/и периферических невропатий UA87843C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP04013636A EP1604656A1 (en) 2004-06-09 2004-06-09 Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)

Publications (1)

Publication Number Publication Date
UA87843C2 true UA87843C2 (ru) 2009-08-25

Family

ID=34925316

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA200612858A UA87843C2 (ru) 2004-06-09 2005-06-08 Применение пептидных соединений для лечения расстройств функционирования мотонейронов или/и периферических невропатий

Country Status (14)

Country Link
US (2) US20050277596A1 (ru)
EP (2) EP1604656A1 (ru)
JP (1) JP2008501753A (ru)
CN (1) CN1960720A (ru)
AT (1) ATE544449T1 (ru)
AU (1) AU2005251459A1 (ru)
BR (1) BRPI0511875A (ru)
CA (1) CA2565102A1 (ru)
EA (1) EA200602220A1 (ru)
MX (1) MXPA06014194A (ru)
TW (1) TW200701984A (ru)
UA (1) UA87843C2 (ru)
WO (1) WO2005120476A2 (ru)
ZA (1) ZA200608594B (ru)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1243262T3 (da) * 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
EP1243263B1 (en) 2001-03-21 2002-11-27 Schwarz Pharma Ag Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
ATE428413T1 (de) * 2003-12-02 2009-05-15 Sanol Arznei Schwarz Gmbh Neue verwendung von peptidverbindungen zur behandlung ovn zentralen neuropathischen schmerzen
EP1579858A1 (en) * 2004-03-26 2005-09-28 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in painful diabetic neuropathy
US20100256179A1 (en) * 2004-03-26 2010-10-07 Ucb Pharma Gmbh Combination therapy for pain in painful diabetic neuropathy
US20070042969A1 (en) * 2004-03-26 2007-02-22 Srz Properties, Inc. Combination therapy for pain in painful diabetic neuropathy
NZ550482A (en) 2004-04-16 2010-08-27 Sanol Arznei Schwarz Gmbh Use of peptidic compounds for the prophylaxis and treatment of chronic headache
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
EP1604655A1 (en) * 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating pain in trigeminal neuralgia
US7427601B2 (en) * 2004-06-24 2008-09-23 Schwarz Pharma Ag Method for treating tremor
CA2573125A1 (en) * 2004-08-27 2006-03-02 Schwarz Pharma Ag Novel use of peptide compounds for treating bone cancer pain, chemotherapy-and nucleoside-induced pain
EP1642889A1 (en) * 2004-10-02 2006-04-05 Schwarz Pharma Ag Improved synthesis scheme for lacosamide
US20060252749A1 (en) * 2005-01-28 2006-11-09 Srz Properties, Inc. Lacosamide for add-on therapy of psychosis
US20070048372A1 (en) * 2005-08-18 2007-03-01 Srz Properties, Inc. Method for treating non-inflammatory osteoarthritic pain
EP1754476A1 (en) * 2005-08-18 2007-02-21 Schwarz Pharma Ag Lacosamide (SPM 927) for treating myalgia, e.g. fibromyalgia
US20070043120A1 (en) * 2005-08-18 2007-02-22 Bettina Beyreuther Therapeutic combination for painful medical conditions
US7902401B2 (en) * 2006-12-14 2011-03-08 Nps Pharmaceuticals, Inc. Fluorinated compounds
ES2450070T5 (es) 2006-06-15 2018-05-08 Ucb Pharma Gmbh Composición farmacéutica que comprende lacosamida y levetiracetam con efecto anticonvulsionante sinérgico
CN101466390B (zh) * 2006-06-15 2014-03-12 优时比制药有限公司 用于治疗难治性癫痫持续状态的肽类化合物
EP1873527A1 (en) * 2006-06-30 2008-01-02 Schwarz Pharma Ag Method for identifying CRMP modulators
EP2099444A4 (en) * 2006-12-14 2012-11-07 Nps Pharma Inc USE OF D-SERIN DERIVATIVES FOR THE TREATMENT OF ANTIBODIES
US20100260716A1 (en) 2007-10-23 2010-10-14 Ucb Pharma Gmbh Compounds for treating demyelination conditions
CA2774569A1 (en) * 2009-09-23 2011-03-31 The University Of North Carolina At Chapel Hill Novel n-benzylamide substituted derivatives of 2-(acylamido)acetic acid and 2-(acylamido)propionic acids: potent neurological agents
WO2011101863A2 (en) 2010-02-19 2011-08-25 Cadila Healthcare Limited Extended release pharmaceutical compositions of lacosamide
EP2468261A1 (en) 2010-12-02 2012-06-27 UCB Pharma GmbH Formulation of lacosamide
NZ610701A (en) 2010-12-02 2015-06-26 Ucb Pharma Gmbh Once daily formulation of lacosamide
WO2017117569A1 (en) 2015-12-30 2017-07-06 Adamas Pharmaceuticals, Inc. Methods and compositions for the treatment of seizure-related disorders
US11278634B1 (en) 2021-02-12 2022-03-22 Extrovis Ag Stable parenteral composition of lacosamide

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US261204A (en) * 1882-07-18 Joel gadbuey
US227961A (en) * 1880-05-25 Envelope-fastener
US101582A (en) * 1870-04-05 Improved refrigerator
US277596A (en) * 1883-05-15 Top-prop nut
DE2413125C2 (de) 1974-03-15 1983-06-30 Schering Ag, 1000 Berlin Und 4619 Bergkamen Indolylacetylaminosäurederivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneipräparate
DE2627069A1 (de) 1975-06-19 1977-01-20 Ajinomoto Kk Verfahren zur herstellung von substituierten schwefelhaltigen l-aminosaeuren
DE2735537A1 (de) 1977-08-06 1979-02-22 Troponwerke Gmbh & Co Kg Indolacetoxyacetylaminosaeurederivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
JPS557242A (en) 1978-06-30 1980-01-19 Tanabe Seiyaku Co Ltd Phenethylamine derivative
FR2480747A1 (fr) 1980-04-17 1981-10-23 Roques Bernard Derives d'acides amines et leur application therapeutique
FR2489319A1 (fr) 1980-08-27 1982-03-05 Clin Midy Derives de l'acide amino-4 butyrique et les medicaments, actifs notamment sur le systeme nerveux central, en contenant
DE3134933A1 (de) 1981-09-03 1983-03-31 Hoechst Ag, 6230 Frankfurt "harnstoffderivate, verfahren zu ihrer herstellung und diese enthaltende medikamente sowie deren verwendung"
DE3678469D1 (de) 1985-02-15 1991-05-08 Res Corp Technologies Inc Aminosaeure-derivate und ihre anwendung zur herstellung eines antikrampfmittels.
US5378729A (en) 1985-02-15 1995-01-03 Research Corporation Technologies, Inc. Amino acid derivative anticonvulsant
JPS61242589A (ja) 1985-04-22 1986-10-28 Mitsui Toatsu Chem Inc Ｌ−含硫アミノ酸の製造方法
PH24782A (en) 1985-10-24 1990-10-30 Sankyo Co Composition containing a penem or carbapenem antibiotic and the use of the same
NZ222045A (en) 1986-08-21 1989-10-27 Res Corp Technologies Inc From diamides up to tetrapeptides for use as anticanvulsants
CA2056911C (en) 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
KR950704280A (ko) 1992-12-11 1995-11-17 베르너 발데크 벤즈아제피논 유도체(Benzazepinone Derivatives)
DE19533023B4 (de) 1994-10-14 2007-05-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
WO1997003677A1 (en) 1995-07-24 1997-02-06 Trustees Of Boston University Inhibition of nmda receptor activity by pregnenolone sulfate derivatives
DE19544687A1 (de) 1995-11-30 1997-06-05 Thomae Gmbh Dr K Aminosäurederivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
GB9601724D0 (en) 1996-01-29 1996-03-27 Merck Sharp & Dohme Therapeutic agents
US5773475A (en) * 1997-03-17 1998-06-30 Research Corporation Technologies, Inc. Anticonvulsant enantiomeric amino acid derivatives
DE19614533A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue alpha-Hydroxysäurederivate, ihre Herstellung und Verwendung
DE19614534A1 (de) 1996-04-12 1997-10-16 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung
US6277825B1 (en) 1996-07-22 2001-08-21 University Of Utah Research Foundation Use of conantokins for treating pain
US6126939A (en) 1996-09-03 2000-10-03 Yeda Research And Development Co. Ltd. Anti-inflammatory dipeptide and pharmaceutical composition thereof
DE19636046A1 (de) 1996-09-05 1998-03-12 Basf Ag Neue Carbonsäurederivate, ihre Herstellung und Verwendung als gemischte ET¶A¶/ET¶B¶-Rezeptorantagonisten
US6420429B1 (en) 1997-12-23 2002-07-16 Yissum Research Development Company Of The Hebrew University Of Jerusalem Brain targeted low molecular weight hydrophobic antioxidant compounds
US6048899A (en) * 1997-03-17 2000-04-11 Research Corporation Tech., Inc. Anticonvulsant enantiomeric amino acid derivatives
AU7937298A (en) 1997-07-08 1999-02-08 Ono Pharmaceutical Co. Ltd. Amino acid derivatives
DE19743140A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19743142A1 (de) 1997-09-30 1999-04-01 Knoll Ag Pharmazeutische Kombinationspräparate
DE19744799A1 (de) 1997-10-10 1999-04-15 Knoll Ag Pharmazeutische Kombinationspräparate
WO1999023078A2 (de) 1997-10-31 1999-05-14 Basf Aktiengesellschaft Neue carbonsäurederivate, die amidseitenketten tragen, ihre herstellung und verwendung als endothelin-rezeptorantagonisten
CA2328197C (en) 1998-04-14 2007-11-20 The General Hospital Corporation Methods for treating neuropsychiatric disorders
GB9816228D0 (en) 1998-07-24 1998-09-23 Pfizer Ltd Isoquinolines
DE10029014A1 (de) 2000-06-15 2001-12-20 Univ Schiller Jena Urokinase-Hemmstoffe
DE10041478A1 (de) 2000-08-24 2002-03-14 Sanol Arznei Schwarz Gmbh Neue pharmazeutische Zusammensetzung
US7112612B2 (en) 2000-11-21 2006-09-26 Ucb S.A. N-alkylated GABA compounds, processes for their preparation and their use as medicaments
DK1243262T3 (da) * 2001-03-20 2006-10-02 Sanol Arznei Schwarz Gmbh Hidtil ukendt anvendelse af en peptidklasse af forbindelser til behandling af ikke-neuropatiske, inflammatoriske smerter
EP1243263B1 (en) 2001-03-21 2002-11-27 Schwarz Pharma Ag Novel use of a peptide class of compound for treating allodynia or other different types of chronic or phantom pain
PL367262A1 (en) 2001-04-26 2005-02-21 Bristol-Myers Squibb Company A pharmaceutical tablet having a high api content
US7687080B2 (en) 2002-11-25 2010-03-30 Taraxos Inc. Treatment of neuropathy
DE10326303A1 (de) 2003-06-11 2004-12-30 Celares Gmbh Reagenzien zur Modifikation von Biopharmazeutika, deren Herstellung und Anwendung
US20050227961A1 (en) 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
EP1604654A1 (en) 2004-05-18 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating dyskinesia
EP1604656A1 (en) 2004-06-09 2005-12-14 Schwarz Pharma Ag Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)

Also Published As

Publication number Publication date
ATE544449T1 (de) 2012-02-15
EP1755577A2 (en) 2007-02-28
ZA200608594B (en) 2008-04-30
JP2008501753A (ja) 2008-01-24
US20050277596A1 (en) 2005-12-15
WO2005120476A2 (en) 2005-12-22
CN1960720A (zh) 2007-05-09
EA200602220A1 (ru) 2007-04-27
BRPI0511875A (pt) 2008-01-15
AU2005251459A1 (en) 2005-12-22
CA2565102A1 (en) 2005-12-22
TW200701984A (en) 2007-01-16
US7718161B2 (en) 2010-05-18
US20090018198A1 (en) 2009-01-15
EP1604656A1 (en) 2005-12-14
MXPA06014194A (es) 2007-03-12
EP1755577B1 (en) 2012-02-08
WO2005120476A3 (en) 2006-02-16

Similar Documents

Publication Publication Date Title
UA87843C2 (ru) Применение пептидных соединений для лечения расстройств функционирования мотонейронов или/и периферических невропатий
MY146509A (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
DE60310991D1 (de) Phenylalaninderivate als hemmer der dipeptidyl peptidase zur behandlung oder prävention von diabetes
DK1414494T3 (da) Hæmmende antistoffer af HER3-aktivitet
DE60336850D1 (en) Substituierte arylcyclopropylacetamide als glucokinaseaktivatoren
GB0318447D0 (en) Therapeutic agents
MX2008002293A (es) Uso novedoso de compuestos peptidicos para tratar dolor muscular.
MA27548A1 (fr) Inhibiteurs heterocycliques beta-amines de la dipeptidyl peptidase pour le traitement ou la prevention du diabete.
WO2007016476A3 (en) Hepatitis c serine protease inhibitors and uses therefor
MY127961A (en) Beta-amino heterocyclic dipetidyl peptidase inhibitors for the treament or prevention of diabetes
BRPI0615223A2 (pt) inibidores das serina proteases
GB0225475D0 (en) Therapeutic agents
EA200601912A1 (ru) Применение пептидных соединений для профилактики и лечения хронической головной боли
MA28176A1 (fr) Inhibiteurs de la forme mutante du kit
MX2007012538A (es) Uso de lactobacillus gg en la manufactura de un medicamento para la prevencion o tratamiento de alergias respiratorias.
DK1453505T3 (da) Anvendelse af pramipexol til behandling af amyotrofisk lateral sklerose
EA200601837A1 (ru) Бензоксазины для лечения заболеваний дыхательных путей
DE602004020649D1 (de) Hdl-verstärkende kombinationstherapie-komplexe
ATE439355T1 (de) 2 aminocarbonyl-substituierte piperazin- oder diaza-cyclische verbindungen als apoptose-protein-inhibitor (iap)-modulatoren
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
MXPA06012566A (es) Tratamiento de enfermedades infecciosas.
ATE489948T1 (de) Behandlung von autoimmunkrankheiten
DE60306934D1 (de) Verwendung von Nitrilenverbindungen als Arztneimittel
EA200400436A1 (ru) Медикаменты для профилактики и лечения бромидроза
NO20053247D0 (no) Anvendelse av levocetirizin ved behandling av vedvarende allergisk rhinitt.